Harvest One Announces New Satipharm Supply Agreement

Published: June 7, 2019

Harvest One Inc., through it’s wholly-owned subsidiary Satipharm Ltd., announced that it has entered into an agreement to distribute their proprietary Satipharm CBD 10mg Gelpell through Holland & Barrett, Europe’s largest retailer of nutritional supplements and wellness products with over 145 years of experience in the health and wellness industry.

Under the terms of the agreement, Harvest One will supply Satipharm CBD 10mg Gelpell to 841 Holland Barrett stores and online via the Holland & Barret website. An initial shipment, which arrived on June 5th, 2019, will be distributed to stores across the UK. Satipharm will be supporting this increase in distribution with education and product training.

“This supply agreement is pivotal to our global strategy. Having a European health and wellness leader like Holland & Barrett trust and carry our product shows the investment in our manufacturing standards and commercial strategy is proving a success” said Grant Froese, CEO of Harvest One. “We plan to build on this valued agreement by growing the demand for Satipharm CBD Gelpell capsules through both instore and online activity.”

“The CBD industry is growing rapidly. We will continue to be at the forefront of that growth through the release of innovative products that can add value to the market” said a spokesperson for Holland & Barrett. “Satipharm CBD Gelpell capsules give our customers a consistent measurable dose of CBD that can be easily taken throughout their day.”

Satipharm does CBD differently. Satipharm CBD GelpellĀ® capsules contain full spectrum hemp extract CBD in a seamless gelatine bead. This bead is placed inside a hard gastro-resistant capsule ensuring the release of CBD in the small intestine. This EU GMP certified product is manufactured in Switzerland to the highest standards under controlled laboratory conditions ensuring that every Satipharm CBD GelpellĀ® capsule delivers a consistent dose of CBD. Satipharm’s product has undergone Stage I and Stage II clinical trials and is proven to have 30% higher bioavailability than other products on the market.

This agreement provides Harvest One’s wholly owned subsidiary Satipharm, a European platform for growth with Satipharm CBD GelpellĀ® capsules now available in most cities across the UK and Ireland.